低剂量阿米替林治疗肠易激综合征的应答预测因素及不同亚型的疗效与耐受性:ATLANTIS 试验的事后分析
ATLANTIS 试验将 463 例肠易激综合征成人随机分为阿米替林组(232 例)与安慰剂组(231 例)。事后分析显示,≥50 岁患者及居住在英格兰最贫困 70% 地区者在部分结局上应答更好,男性、患者健康问卷-12 评分较高及腹泻型肠易激综合征者疗效更强,各亚型副作用相似。
要点
- ≥50 岁患者阿米替林对 IBS-SSS 的疗效优于 <50 岁者(交互作用 p=0.048)。
- 居住在英格兰最贫困 70% 地区者腹痛改善 ≥30% 的 OR 为 2.70(95%CI 1.52–4.77)。
- 各肠易激综合征亚型中阿米替林副作用相似,未见某一亚型存在有害效应。
核心结论
- 探索性分析表明阿米替林在任何特定肠易激综合征亚型中不太可能有害,并可能有助于识别阿米替林更有效的患者。
研究设计与样本
- ATLANTIS 试验的事后分析,随机纳入 463 例肠易激综合征成人,阿米替林组 232 例、安慰剂组 231 例。
主要发现
- ≥50 岁与 <50 岁患者阿米替林疗效存在数量差异:IBS 严重程度评分系统交互作用 p=0.048,≥50 岁亚组平均差 -46.5(95%CI -74.2 至 -18.8,p=0.0010)。
- 主观总体缓解评估交互作用 p=0.068,≥50 岁亚组 OR 2.59(95%CI 1.47 至 4.55,p=0.0010)。
- 居住在英格兰最贫困 70% 地区与最不贫困 30% 地区者腹痛改善 ≥30% 存在差异:交互作用 p=0.021,最贫困 70% 亚组 OR 2.70(95%CI 1.52 至 4.77,p=0.0007)。
- 男性、患者健康问卷-12 评分较高及腹泻型肠易激综合征者疗效更强。
- 几乎所有肠易激综合征亚型中,IBS-SSS 各组分平均差异均倾向阿米替林,且副作用相似。
局限性
- 原文为事后探索性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low-dose amitriptyline, a tricyclic antidepressant (TCA), was superior to placebo for irritable bowel syndrome (IBS) in the AmitripTyline at Low-dose ANd Titrated for Irritable bowel syndrome as Second-line treatment (ATLANTIS) trial. OBJECTIVE: To perform post hoc analyses of ATLANTIS for predictors of response to, and tolerability of, a TCA. DESIGN: ATLANTIS randomised 463 adults with IBS to amitriptyline (232) or placebo (231). We examined the effect of baseline demographic and disease-related patient characteristics on response to amitriptyline and the effect of amitriptyline on individual symptoms and side effects by subtype. RESULTS: There was a quantitative difference in amitriptyline effectiveness in those ≥50 years vs <50 on the IBS severity scoring system (IBS-SSS) (interaction p=0.048, mean difference in ≥50 years subgroup -46.5; 95% CI -74.2 to -18.8, p=0.0010), and subjective global assessment of relief (interaction p=0.068, OR in ≥50 years subgroup 2.59; 95% CI 1.47 to 4.55, p=0.0010), and those in the 70% most deprived areas of England compared with the 30% least deprived for a ≥30% improvement in abdominal pain (interaction p=0.021, OR in 70% most deprived subgroup 2.70; 95% CI 1.52 to 4.77, p=0.0007). Stronger treatment effects were seen in men, with higher Patient Health Questionnaire-12 scores, and with IBS with diarrhoea. Mean differences in individual IBS-SSS components favoured amitriptyline, and side effects were similar, across almost all IBS subtypes. CONCLUSION: These exploratory analyses demonstrate there are unlikely to be deleterious effects of amitriptyline in any particular IBS subtype and could help identify patients in whom amitriptyline may be more effective. TRIAL REGISTRATION NUMBER: ISRCTN48075063.
引用
- Wright-Hughes A, Ow PL, Alderson SL, et al. Predictors of response to low-dose amitriptyline for irritable bowel syndrome and efficacy and tolerability according to subtype: post hoc analyses from the ATLANTIS trial. Gut. 2025. PMID: 39863398. doi:10.1136/gutjnl-2024-334490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。